Clinical trials: Etoposide, completed
Refractory Neuroblastoma, Soft Tissue Cancer
A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma
The purpose of this study is to evaluate safety and efficacy of naxitamab, granulocyte macrophage Colony Stimulating Factor (GM CSF) and Isofosfamide/Carboplatin/Etoposide (NICE) for Patients With Relapsed /Refractory, soft…
- Trial name
- NICE (NCT06438614)
- Testing
- HITS, Naxitamab + GM-CSF cycles, NICE
- Where
- Spain
- Volunteers
- 47 people
- Sponsor
- Fundació Sant Joan de Déu
Osteosarcoma, Localised High Grade Osteosarcoma of the Limbs
Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children
The purpose of this study is to compare two preoperative chemotherapy regimens based on high-dose methotrexate courses given alternately either with doxorubicin or with etoposide-ifosfamide.
- Trial name
- NCT00180908
- Testing
- Etoposide, Ifosfamide, Methotrexate, Doxorubicin, Methotrexate
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy used to…
- Trial name
- NCT00002674
- Testing
- filgrastim, cytarabine, etoposide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of selinexor when given together with etoposide with or without mitoxantrone hydrochloride and cytarabine in treating patients with acute myeloid leukemia that has…
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Trial name
- NCT02299518
- Testing
- mitoxantrone hydrochloride, etoposide, cytarabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Alice Mims
Neuroblastoma
Combination Chemotherapy Followed by Surgery in Treating Infants With Newly Diagnosed Neuroblastoma.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00025597
- Testing
- carboplatin, cyclophosphamide, doxorubicin hydrochloride
- Where
- 11 sites in Austria, Belgium and 9 more
- Sponsor
- European Infant Neuroblastoma Study Group - 1999
Relapsed Acute Leukemia, Refractory Acute Leukemia
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen…
- Trial name
- NCT00410423
- Testing
- Bortezomib with mitoxantrone, etoposide and cytarabine, Bortezomib 1.0mg/m^2, Bortezomib 1.3mg/m^2
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Testicular Cancer
Determining the Clinical Relevance of the inTeraction Between AprepitaNt aNd EtoposiDe
Rationale: In pharmacokinetic studies, aprepitant was shown to be a moderate inhibitor of CYP3A4 activity. Etoposide is metabolised by CYP3A4.
- Trial name
- TANNED (NCT04935255)
- Testing
- Blood sampling - Pharmacokinetic assessment
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Radboud University Medical Center
Acute Myeloid Leukemia (AML)
Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation
This is a randomized, Phase-III, two-arm, open-label, multi-center study in adult patients with AML and NPM1 mutation ineligible for intensive chemotherapy.
- Trial name
- NCT01237808
- Testing
- Cytarabine, Etoposide, All-trans retinoic acid (ATRA)
- Where
- 33 sites in Germany
- Volunteers
- 144 people
- Sponsor
- University of Ulm
Metastatic, Cerebral Primitive Neuroectodermal Tumors
Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years
Primary objective : To increase the 3 year progression-free survival from 40% to 60%. Patients included : metastatic, cerebral primitive neuroectodermal tumors in children aged over 5 years.
- Trial name
- NCT00936156
- Testing
- Chemotherapy (carboplatin, etoposide, thiotepa)
- Where
- France
- Volunteers
- 68 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Lung Cancer
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, and docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00062439
- Testing
- cisplatin, docetaxel, etoposide
- Where
- 154 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003158
- Testing
- carboplatin, etoposide, paclitaxel
- Where
- 86 sites in United States
- Volunteers
- 96 people
- Sponsor
- SWOG Cancer Research Network
Brain and Central Nervous System Tumors
Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006258
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 3 sites in United States, Canada
- Sponsor
- Children's Hospital Los Angeles
Lymphoma
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
This pilot clinical trial studies biological therapy in treating patients with acquired immune deficiency syndrome (AIDS)-related lymphoma undergoing stem cell transplant.
- Trial name
- NCT00569985
- Testing
- lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, carmustine, cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- City of Hope Medical Center
Malignant Childhood Neoplasm
Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies
Many of the pediatric malignancies are not curable on progression on front line or 2nd line chemotherapy. Further therapy with conventional drugs imposes many side effects and decreases the QOL.
- Trial name
- NCT01858571
- Testing
- Low dose chemotherapy
- Where
- India
- Volunteers
- 108 people
- Sponsor
- All India Institute of Medical Sciences
Kidney Cancer
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00002611
- Testing
- dactinomycin, filgrastim, cyclophosphamide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 3,031 people
- Sponsor
- Children's Oncology Group
T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous injection.
- Conditions
- T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
- Trial name
- NCT01445535
- Testing
- Rituximab, Etoposide, Siplizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Follicular Lymphoma
High-Dose Therapy Treatment in Patients With Follicular Lymphoma
Follicular lymphomas are a subgroup of B-cell non-Hodgkin lymphomas, accounting for 15% to 30% of newly diagnosed lymphomas.1-3 Median survival varies from 5 to 10 years depending on the prognostic factors at diagnosis and…
- Trial name
- NCT00696735
- Testing
- chemotherapy, high dose therapy and autologous stem cell transplantation
- Where
- 2 sites in France
- Volunteers
- 172 people
- Sponsor
- French Innovative Leukemia Organisation
Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer
First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer
The purpose of this study is to evaluate the role of an additional intraperitoneal chemotherapy with cisplatin and etoposide in bulky advanced epithelial ovarian cancer.
- Conditions
- Bulky Stage IIIC and IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- AICE (NCT01669226)
- Testing
- PEip (weekly) and TCiv, TCiv
- Where
- 7 sites in China
- Volunteers
- 215 people
- Sponsor
- Shanghai Gynecologic Oncology Group
Neuroblastoma
Combination Chemotherapy in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003093
- Testing
- filgrastim, sargramostim, carboplatin
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 573 people
- Sponsor
- Children's Oncology Group
Leukemia
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002638
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Nebraska